Humulin R U-500

Small molecule

BBiodel

Humulin R U-500 is one of 38 small molecule programs targeting Insulin resistance. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Insulin ResistancePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

1 2

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 3

Jardiance

Boehringer Ingelheim

Phase 3

2 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 5

Parlodel

VVeroScience

Phase 3

1 6

Glucophage

Boehringer Ingelheim

Phase 3

1 7

Farxiga

AstraZeneca

Phase 2

2 8

Lupron

AbbVie

Phase 2

1 9

Metformin Hcl

Boehringer Ingelheim

Phase 3

2 10

Myalept

Chiesi Farmaceutici S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Intraperitoneal

NCT07341373

Clinical

Trials by Indication[1]

Intraperitoneal1 trial

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

Recruiting·PPortal Diabetes, Inc.·Phase 1·NCT07341373·25 enrolled

TED1 trial

Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500

Completed·BBiodel·Phase 1/2·NCT02212951·12 enrolled

MPA1 trial

Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects

Completed·BBiocon Limited·Phase 1·NCT05413863·78 enrolled

Insulin resistance1 trial

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

Completed·BBiodel·Phase 1/2·NCT02324309·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Humulin R U-500. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Humulin R U-500 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Humulin R U-500. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biodel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBiodel

Humulin R U-500

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Intraperitoneal1 trial

TED1 trial

MPA1 trial

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News